AbbVie, Enbridge, Realty Income: Top Dividend Stocks for 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
Source: Fool
- AbbVie's Strong Returns: AbbVie (ABBV), a 'Dividend King' with 50 consecutive years of dividend increases, currently offers a 3.1% yield; despite rising share prices, its P/E ratio remains below 16, indicating strong value and potential for continued growth and shareholder returns.
- Enbridge's Growth Potential: Enbridge (ENB) boasts a 6.1% dividend yield and has increased dividends for 30 years, with projected growth opportunities of $50 billion by 2030, particularly in its gas transmission business to meet rising demand from data centers.
- Realty Income's Diversified Investments: Realty Income (O) attracts investors with a 5.5% yield and a record of 112 consecutive dividend increases, owning 15,542 properties across 92 industries, showcasing resilience and growth potential amid economic fluctuations.
- Market Opportunities Driven by Data Centers: The surge in data center construction benefits AbbVie, Enbridge, and Realty Income, highlighting their sustained investment appeal through 2026 and beyond due to increasing demand for natural gas and real estate.
Analyst Views on ABBV
Wall Street analysts forecast ABBV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ABBV is 253.26 USD with a low forecast of 218.00 USD and a high forecast of 289.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
22 Analyst Rating
15 Buy
7 Hold
0 Sell
Moderate Buy
Current: 216.750
Low
218.00
Averages
253.26
High
289.00
Current: 216.750
Low
218.00
Averages
253.26
High
289.00
About ABBV
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
